The reduction in the price target by Barclays, despite maintaining an Overweight rating, could lead to a negative short-term sentiment among investors. This adjustment reflects a revised valuation basis by the analyst, potentially due to factors affecting Teladoc's market position or financial outlook. Such a move often results in a short-term negative impact on the stock price as investors adjust their expectations based on the new target.